12 assets in Endometrial Serous Adenocarcinoma

Therapeutic assets addressing Endometrial Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Endometrial Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (61)
Capivasertib Endometrial Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Durvalumab Endometrial Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Endometrial Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Endometrial Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Cdx 1140 Endometrial Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Amt-151 Endometrial Serous Adenocarcinoma	Multitude Therapeutics Inc.	P1	CC (43)
Atezolizumab Endometrial Serous Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Sapanisertib Endometrial Serous Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Dordaviprone Endometrial Serous Adenocarcinoma	UNC Lineberger Comprehensive Cancer Center	P1	C (39)
Bms-986463 Endometrial Serous Adenocarcinoma	Bristol-Myers Squibb	P1	NR ()
Vls-1488 Endometrial Serous Adenocarcinoma	Volastra Therapeutics, Inc.	P1/2	NR ()